BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Atopic dermatitis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for atopic dermatitis: 197 (109 sponsors; 46 newly posted in the last 180 days, 10 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 24.4, rank 14 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 31, Phase 2 62, Phase 3 50, Phase 4 3, N/A 51.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Pfizer PFE14NA 6, P1 1, P2 2, P3 542
Sanofi SNY16NA 9, P3 4, P4 2, P2 124
AbbVie ABBV9P2 2, NA 3, P3 414
Keymed Biosciences Co.Ltd5P3 3, P2 201
Almirall, S.A.4P3 3, NA 111
Shanghai Mabgeek Biotech.Co.Ltd4P3 2, P2 211
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM4P3 2, P1 220
Jiangsu vcare pharmaceutical technology co., LTD3P3 2, P2 101
Nektar Therapeutics NKTR3P2 1, P3 220
Qilu Pharmaceutical Co., Ltd.3P2 1, P3 202
Eli Lilly and Company LLY2P3 200
Otsuka Pharmaceutical Co., Ltd.2P3 202
Akeso3P2 2, P3 100
Galderma R&D3P2 1, NA 1, P3 120
Guangdong Hengrui Pharmaceutical Co., Ltd3P2 2, P3 100
Incyte Corporation INCY3NA 2, P3 100
Innovent Biologics (Suzhou) Co. Ltd.3P3 1, P2 1, P1 112
Arcutis Biotherapeutics, Inc. ARQT2P3 1, P1 110
EHL Bio Co., Ltd.2P2 1, P3 100
Hangzhou Highlightll Pharmaceutical Co., Ltd new entrant2P2 1, P3 120
LEO Pharma2P3 1, NA 110
Beijing InnoCare Pharma Tech Co., Ltd.1P3 101
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.1P3 100
Jiangsu Genscend Biopharmaceutical Co., Ltd1P3 101
medac GmbH1P3 100

New-entrant sponsors: Hangzhou Highlightll Pharmaceutical Co., Ltd.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-19 est.P2Janssen Research & Development, LLCNCT07230860 A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisDermatitis, Atopicactive not recruiting189
2026-11-25 est.P3Beijing InnoCare Pharma Tech Co., Ltd.NCT06775860 ICP-332 in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitisrecruiting552
2026-12 est.P3Otsuka Pharmaceutical Co., Ltd.NCT07173478 A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisAtopic Dermatitis (AD)not yet recruiting156
2026-12 est.P2Enveda TherapeuticsNCT07298395 Study of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisAtopic Dermatitis (AD)recruiting105
2026-12-31 est.P1/P2Bio-Thera SolutionsNCT06094179 Evaluate the Safety, Tolerability of BAT6026Dermatitis, Atopicactive not recruiting33
2027-01 est.P3AbbVie ABBVNCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to SevereAtopic Dermatitisactive not recruiting99
2027-01-05 est.P3Shanghai Mabgeek Biotech.Co.LtdNCT07540442 A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic DermatitisDermatitis, Atopicnot yet recruiting180
2027-01-20 est.P2/P3Turn Therapeutics TTRXNCT07355075 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic DermatiEczema Atopic Dermatitis; Eczema; Atopic Dermatitisrecruiting190
2027-01-31 est.P2Dermavon Holdings LimitedNCT07465120 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With ModerModerate to Severe Atopic Dermatitisnot yet recruiting160
2027-02 est.P2AbbVie ABBVNCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis ReceivinHidradenitis Suppurativa; Atopic Dermatitisrecruiting60
2027-02 est.P3Keymed Biosciences Co.LtdNCT07106372 A Study of Stapokibatrt in Children Subjects With Atopic DermatitisAtopic Dermatitisnot yet recruiting240
2027-02 est.P3Otsuka Pharmaceutical Co., Ltd.NCT07184645 A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisAtopic Dermatitis (AD)not yet recruiting198

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-12 est.P2Pfizer PFENCT05995964 A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisAtopic Dermatitisactive not recruiting507
2026-11 est.P2Apogee Therapeutics, Inc. APOGNCT06395948 A Study Evaluating APG777 in Atopic DermatitisAtopic Dermatitisactive not recruiting470
2026-11 est.P3AbbVie ABBVNCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabAtopic Dermatitisactive not recruiting184
2026-11 est.P3medac GmbHNCT06239311 Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.Moderate to Severe Atopic Dermatitisrecruiting277
2026-10-16P3LEO PharmaNCT06311682 A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DAtopic Dermatitisrecruiting195
2026-10-09P3Regeneron Pharmaceuticals REGNNCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Atopic Dermatitiscompleted880
2026-10 est.P2Triveni BioNCT07167758 A Study Evaluating TRIV-509 in Atopic DermatitisAtopic Dermatitisactive not recruiting95
2026-09-23P2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07175233 A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic DermatitisAtopic Dermatitis (AD)active not recruiting184
2026-09-21P2Aclaris Therapeutics, Inc. ACRSNCT07011706 ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitis; Atopic; Dermatitis; AD; Eczemaactive not recruiting110
2026-09 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT07211542 A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic DermatitisModerate-to-severe Atopic Dermatitisrecruiting75
2026-08-31P3Galderma R&DNCT03989206 Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic DermatitisModerate-to-Severe Atopic Dermatitiscompleted1935
2026-08-30 est.P3Keymed Biosciences Co.LtdNCT06495229 Study of CM310 in Adolescent Subjects With Atopic DermatisAtopic Dermatitisactive not recruiting180
2026-08-26P3Guangdong Hengrui Pharmaceutical Co., LtdNCT06468956 Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisModerate to Severe Atopic Dermatitiscompleted652
2026-08-18P2Innovent Biologics (Suzhou) Co. Ltd.NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitisterminated18
2026-08-07P3Incyte Corporation INCYNCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisAtopic Dermatitisactive not recruiting159
2026-07-23P2Evommune, Inc. EVMNNCT07150845 Phase 2b Study of EVO756 in Adults With Atopic DermatitisAtopic Dermatitiscompleted121
2026-07-22P2Hoffmann-La RocheNCT06863961 A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitisactive not recruiting162
2026-07-18 est.P2Keymed Biosciences Co.LtdNCT06947980 Study of CM512 in Patients With Moderate-to-Severe Atopic DermatitisAtopic Dermatitisrecruiting200
2026-07-13P2HK inno.N CorporationNCT07073677 A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult PatientsMild to Moderate Atopic Dermatitisrecruiting162
2026-07-01P3Amgen AMGNNCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AAtopic Dermatitisterminated2621
2026-06-30 est.P3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT07042126 Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic DermatitisDermatitis, Atopicrecruiting180
2026-05-25P1/P2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFMNCT06324812 Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic DermatitisDermatitis, Atopiccompleted128

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "atopic dermatitis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.